APA (7th ed.) Citation

MJ, M., JM, M., K, L., P, H., M, G., MA, C., . . . HI, S. (2021). Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503). European urology oncology, 4(4), 543. https://doi.org/10.1016/j.euo.2021.04.008

Chicago Style (17th ed.) Citation

MJ, Morris, et al. "Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)." European Urology Oncology 4, no. 4 (2021): 543. https://doi.org/10.1016/j.euo.2021.04.008.

MLA (9th ed.) Citation

MJ, Morris, et al. "Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)." European Urology Oncology, vol. 4, no. 4, 2021, p. 543, https://doi.org/10.1016/j.euo.2021.04.008.